Brandywine Global Investment Management LLC Has $3.43 Million Position in Collegium Pharmaceutical, Inc. $COLL

Key Points

• Brandywine Global Investment Management LLC increased its stake in Collegium Pharmaceutical by 13.7%, owning a total of 114,763 shares valued at approximately $3.4 million as of the latest SEC filing.
• Collegium Pharmaceutical's Board of Directors has initiated a $150 million share buyback program, allowing the purchase of up to 15.4% of outstanding shares, signaling confidence in the stock's valuation.
• Several analysts have upgraded Collegium Pharmaceutical's rating to "strong-buy", with price targets set as high as $44, reflecting positive market sentiment.

Brandywine Global Investment Management LLC boosted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 13.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,763 shares of the specialty pharmaceutical company's stock after acquiring an additional 13,792 shares during the period. Brandywine Global Investment Management LLC owned 0.36% of Collegium Pharmaceutical worth $3,426,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Wealthquest Corp bought a new position in shares of Collegium Pharmaceutical during the first quarter worth about $62,000. Virtus Fund Advisers LLC lifted its holdings in Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 565 shares during the last quarter. FORA Capital LLC acquired a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $223,000. XTX Topco Ltd acquired a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $236,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in Collegium Pharmaceutical in the 1st quarter valued at about $244,000.

Insider Transactions at Collegium Pharmaceutical

In other news, Director Gino Santini sold 5,405 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $37.19, for a total value of $201,011.95. Following the completion of the sale, the director directly owned 95,042 shares of the company's stock, valued at $3,534,611.98. This represents a 5.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John Gordon Freund sold 11,659 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $34.36, for a total transaction of $400,603.24. Following the completion of the sale, the director directly owned 23,129 shares of the company's stock, valued at $794,712.44. This trade represents a 33.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,915 shares of company stock valued at $1,614,825 over the last three months. 2.51% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

COLL has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Piper Sandler reissued a "neutral" rating and issued a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Finally, HC Wainwright raised shares of Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 price target for the company in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $42.33.

Collegium Pharmaceutical Trading Down 1.0%

COLL stock traded down $0.41 during mid-day trading on Friday, reaching $39.11. 447,830 shares of the stock traded hands, compared to its average volume of 413,800. The company has a current ratio of 1.18, a quick ratio of 1.10 and a debt-to-equity ratio of 3.27. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $42.29. The company has a market cap of $1.23 billion, a P/E ratio of 37.61 and a beta of 0.68. The stock's fifty day moving average is $32.42 and its 200-day moving average is $30.05.

Collegium Pharmaceutical declared that its board has approved a share repurchase program on Monday, July 7th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the specialty pharmaceutical company to buy up to 15.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.